In the present report, we assessed the ability of DYRK2 to influence the chemosensitivity of 5-FUR LoVo cells via modulating the induction of the EMT in these CRC cells, thus increasing the sensitivity of these cells to 5-FU treatment. This evidence concerns the gene DYRK2 and colorectal carcinoma.